Table 2.
Anti-angiogenesis drugs currently approved for patient use
| Drug | Success | Limitation | References |
|---|---|---|---|
| Monoclonal anti-VEGF antibody | |||
| Bevacizumab (Avastin) | Improved PFS in the majority of trials | No OS in the majority of trials | [216–220] |
| Ramucirumab (Cyramza) | Improved PFS in the majority of trials | No OS in the majority of trials | [221–223] |
| Chimeric VEGF/PIGF neutralizing receptor | |||
| Ziv-aflibercept (VEGF trap) | Improved PFS in CRC and NSCLC | Little to no OS improvement; no PFS improvement in PACA | [224–226] |
| Small-molecule VEGFR TKI | |||
| Sorafenib (Nexavar) | Improved PFS in RCC improved OS in HCC | No OS improvement in RCC; no PFS or OS improvement in metastatic melonma or NSCLC | [225, 227, 228] |
| Sunitinib (Sutent) | Improved PFS in advanced/metastatic RCC, GIST, pancreatic NETs, and PRCA; increased OS in RCC and pancreatic NETs | No OS improvement in the majority of trials, no PFS or OS improvement in metastatic BRCA or CRCA | [225, 229–231] |
| Pazopanib (Votrient) | Improved PFS in RCC and STS | No OS improvement | [232, 233] |
| Vandetanib (Caprelsa) | Improved PFS in metastatic MTC | No OS improvement; little/no PFS improvement in metastatic NSCLC | [225, 234, 235] |
| Vatalanib/PTK787 | – | No OS improvement; no/little PFS improvement in metastatic CRCA | [225] |
| Cediranib | – | No improvement in OS or PFS | [236] |
| Axitinib (Inlyta) | Improved PFS in RCC | No OS improvement; no PFS improvement in metastatic PACA | [237] |
| Everolimus (Afinitor) | Improved PFS in BRCA | No OS improvement | [165–167] |
BRCA breast cancer, CRC colorectal cancer, GIST gastrointestinal stromal tumor, HPC hepatocellular carcinoma, MTC medullary thyroid carcinoma, NET neuroendocrine tumor, NSCLC non-small-cell lung cancer, OS overall survival, PACA pancreatic cancer, PFS progression-free survival, RCC renal cell carcinoma